Primary-outcome results across pivotal trials
Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.
| Trial | Indication | Primary endpoint | Arm | Value |
|---|---|---|---|---|
| NCT00004031 | Lymphoma, Large B-Cell, Diffuse | 2-year Overall Survival Rates up to 2 years post registration | CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | 73.7 percentage of participants |
| CHOP/CHOP-R x 3 | 71.1 percentage of participants | |||
| NCT00004031 | Lymphoma, Large B-Cell, Diffuse | 2 Year Progression-free Survival From registration until death | CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | 69.1 percentage of participants |
| CHOP/CHOP-R x 3 | 55.4 percentage of participants | |||
| NCT00006721 | Lymphoma | Overall Survival at 2 Years 0-2 years | CHOP + Rituximab | 97 percentage of participants |
| CHOP + Tositumomab | 93 percentage of participants | |||
| NCT00006721 | Lymphoma | Overall Survival at 5 Years 0-5 years | CHOP + Rituximab | 92 percentage of participants |
| CHOP + Tositumomab | 86 percentage of participants | |||
| NCT00006721 | Lymphoma | Progression-free Survival at 2 Years 0-2 years | CHOP + Rituximab | 76 percentage of participants |
| CHOP + Tositumomab | 80 percentage of participants | |||
| NCT00006721 | Lymphoma | Progression-free Survival at 5 Years 0-5 years | CHOP + Rituximab | 60 percentage of participants |
| CHOP + Tositumomab | 66 percentage of participants | |||
| NCT00075946 | Lymphoma | Time to Rituximab Failure (TTRF) Assessed (by restaging CT scans) 26 weeks ± 2 weeks from each rituximab treatment (including induction), counting the first rituximab dose as Day 1, until rituximab failure observed or July 17, 2013, whichever occurred first. | Rituximab Retreatment: Follicular Patients | 3.92 years |
| Rituximab Retreatment: Non-Follicular Patients | 1.39 years | |||
| Rituximab Scheduled: Follicular Patients | 4.32 years | |||
| Rituximab Scheduled: Non-Follicular Patients | 4.83 years | |||
| NCT00078949 | Lymphoma, Large B-Cell, Diffuse | Event-free Survival of Patients on Maintenance Randomization (Period 2) during the period 2 (up to10 years) | Maintenance | 53 participants |
| Observation | 65 participants | |||
| NCT00078949 | Lymphoma, Large B-Cell, Diffuse | Response Rate of Patients After 2 Courses of Chemotherapy After 2 cycle of treatment | Salvage DHAP | 44.0 percentage of response |
| Salvage GDP | 45.2 percentage of response | |||
| NCT00078949 | Lymphoma, Large B-Cell, Diffuse | Transplantation Rate of Patients After 2 Courses of Chemotherapy During period 1 (salvage chemotherapy) | Salvage DHAP | 48.9 percentage of transplantation |
| Salvage GDP | 51.0 percentage of transplantation | |||
| NCT00087529 OLYMPUS | Multiple Sclerosis | Percentage of Participants With CDP 96 weeks (from Screening to Week 96, and at least 12 weeks after initial progression) | Placebo | 36.1 percentage of participants |
| Rituximab | 28.4 percentage of participants | |||
| NCT00087529 OLYMPUS | Multiple Sclerosis | Time to Confirmed Disease Progression (CDP) 96 weeks (from Screening to Week 96, and at least 12 weeks after initial progression) | Placebo | NA weeks |
| Rituximab | NA weeks | |||
| NCT00088530 | Lymphoma, Non-Hodgkin | Complete Response (CR) and Complete Response Unconfirmed (CRu) EOT; approximately 6 months | Comparator Group | 7.1 percentage of randomized patients |
| Comparator Group | 5.7 percentage of randomized patients | |||
| Experimental Group | 20.0 percentage of randomized patients | |||
| Experimental Group | 24.3 percentage of randomized patients | |||
| NCT00090051 | Leukemia, Lymphocytic, Chronic, B-Cell | Final Analysis: Time to Progression-Free Survival Event Median observation time was approximately 5 years | Fludarabine+Cyclophosphamide (FC) | 683.0 Days |
| Fludarabine+Cyclophosphamide+Rituximab (FCR) | 969.0 Days | |||
| NCT00090051 | Leukemia, Lymphocytic, Chronic, B-Cell | Number of Participants With Progression-free Survival (PFS) Events Assessed by the Independent Review Committee (IRC) Mean observation time at time of analysis was approximately 26 months | Fludarabine+Cyclophosphamide (FC) | 148 participants |
| Fludarabine+Cyclophosphamide (FC) | 128 participants | |||
| Fludarabine+Cyclophosphamide+Rituximab (FCR) | 139 participants | |||
| Fludarabine+Cyclophosphamide+Rituximab (FCR) | 137 participants | |||
| NCT00090051 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC) Mean observation time at time of analysis was approximately 26 months | Fludarabine+Cyclophosphamide (FC) | 660 Days |
| Fludarabine+Cyclophosphamide+Rituximab (FCR) | 813 Days | |||
| NCT00096460 | Lymphoma, Follicular | Lymphoma Progression-free Survival Three years post-Hematopoietic Stem Cell Transplant (HSCT) | Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | 6 participants |
| Autologous Hematopoietic Stem Cell Transplant (HSCT) | 13 participants | |||
| NCT00104299 RAVE | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Disease Remission 6 months post-randomization | Control Group | 52 Participants |
| Rituximab | 63 Participants | |||
| NCT00118209 | — | Progression-Free Survival Rate at 2 and 5 Years Up to 5 years post-registration | Arm A - R-CHOP | 66.0 percentage of participants |
| Arm A - R-CHOP | 75.5 percentage of participants | |||
| Arm B - DA-EPOCH-R | 78.9 percentage of participants | |||
| Arm B - DA-EPOCH-R | 68.0 percentage of participants | |||
| NCT00137969 EXPLORER | Lupus Erythematosus, Systemic | Number of Participants Who Achieved a Major Clinical Response (MCR), Partial Clinical Response (PCR), or Nonclinical Response (NCR) Defined by British Isles Lupus Assessment Group (BILAG) Scores Over The 52-week Treatment Period From baseline to 52 weeks | Placebo + Prednisone | 63 Participants |
| Placebo + Prednisone | 11 Participants | |||
| Placebo + Prednisone | 14 Participants | |||
| Rituximab 1000 mg + Prednisone | 29 Participants | |||
| Rituximab 1000 mg + Prednisone | 119 Participants | |||
| Rituximab 1000 mg + Prednisone | 21 Participants | |||
| NCT00210353 | Lymphoma, B-Cell, Marginal Zone | Event-free-survival (EFS) 5 years | ARM A - Chlorambucil | 51 percentage of patients |
| ARM B - Rituximab + Chlorambucil | 68 percentage of patients | |||
| ARM C (Since April 2006) - Rituximab | 51 percentage of patients | |||
| NCT00254163 | Leukemia, Lymphocytic, Chronic, B-Cell | Infection Rate 6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity | FCR Arm | 31.4 percentage of participants |
| PCR Arm | 36.5 percentage of participants | |||
| NCT00266227 SUNRISE | Arthritis, Rheumatoid | Retreated Subjects With an American College of Rheumatology 20% (ACR20) Response at Week 48 Relative to Baseline 48 Weeks | Arm A: Rituximab Retreatment | 170 Participants |
| Arm B: Placebo Retreatment | 70 Participants | |||
| NCT00268983 | Lymphoma, Non-Hodgkin | Event-free Survival (EFS) From the date of randomization to the first occurrence of progressive disease, death, or additional Non-Hodgkins Lymphoma (median follow-up for the Rituximab and TST/I-131 TST groups was 62 and 91.5 months, respectively) | Rituximab 375 mg/m^2 | 9 Months |
| TST/I-131 TST | NA Months | |||
| NCT00268983 | Lymphoma, Non-Hodgkin | Progression-free Survival From first dose of treatment until disease progression or death, whichever came first (median follow-up for the Rituximab and TST/I-131 TST groups was 62 and 91.5 months, respectively) | Rituximab 375 mg/m^2 | 9 months |
| TST/I-131 TST | NA months | |||
| NCT00269113 | Lymphoma, Non-Hodgkin | Percentage of Participants Achieving CR or PR at the End of Therapy Following completion of 6 cycles (24 weeks) | Mitoxantrone, Chlorambucil, Prednisolone (MCP) | 75.0 percentage of participants |
| Rituximab + MCP | 92.4 percentage of participants | |||
| NCT00278408 | Lymphoma, Large B-Cell, Diffuse | 3 Years Event-free Survival Each patient will be observed for 3 years starting from completion of treatment. | Interventional: 6 R-CHOP-14 + Radiotherapy for Patients With Radiotherapy Indication | 123 Participants |
| Interventional: 6 R-CHOP-14 for Patients With Radiotherapy Indication | 56 Participants | |||
| Interventional: 6 R-CHOP-14 for Patients Without Radiotherapy Indication | 92 Participants | |||
| Interventional: 6 R-CHOP-21 + Radiotherapy for Patients With Radiotherapy Indication | 126 Participants | |||
| Interventional: 6 R-CHOP-21 for Patients With Radiotherapy Indication | 51 Participants | |||
| Interventional: 6 R-CHOP-21 for Patients Without Radiotherapy Indication | 89 Participants | |||
| NCT00281918 CLL-8 | Leukemia, Lymphocytic, Chronic, B-Cell | Final Analysis: Time to Progression-free Survival Event Median observation time was approximately 66.4 months | Fludarabine+Cyclophosphamide (FC) | 998.0 Days |
| Fludarabine+Cyclophosphamide+Rituximab (FCR) | 1703.0 Days | |||
| NCT00281918 CLL-8 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) Median observation time at time of analysis was approximately 21 months | Fludarabine+Cyclophosphamide (FC) | 981.0 Days |
| Fludarabine+Cyclophosphamide+Rituximab (FCR) | 1212.0 Days | |||
| NCT00282347 LUNAR | Lupus Nephritis | Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 Week 52 | Placebo | 30.6 Percentage of participants |
| Placebo | 54.2 Percentage of participants | |||
| Placebo | 15.3 Percentage of participants | |||
| Rituximab | 30.6 Percentage of participants | |||
| Rituximab | 43.1 Percentage of participants | |||
| Rituximab | 26.4 Percentage of participants | |||
| NCT00299104 IMAGE | Arthritis, Rheumatoid | Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52 Baseline and week 52 | Placebo + Methotrexate | 1.079 Score on a scale (±4.0934 Standard Deviation) |
| Rituximab (0.5 g x 2) + Methotrexate | 0.646 Score on a scale (±1.9196 Standard Deviation) | |||
| Rituximab (1.0 g x 2) + Methotrexate | 0.359 Score on a scale (±1.0095 Standard Deviation) | |||
| NCT00299130 SERENE | Arthritis, Rheumatoid | Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 Baseline and Week 24 | Placebo + MTX | 23.3 percentage of participants |
| Rituximab 2 x 0.5 g + MTX | 54.5 percentage of participants | |||
| Rituximab 2 x 1.0 g + MTX | 50.6 percentage of participants | |||
| NCT00312845 | Lymphoma, Non-Hodgkin | Progression Free Survival Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months. | Bortezomib + Rituximab | 389 days |
| Rituximab | 334 days | |||
| NCT00355199 | Lymphoma, Large B-Cell, Diffuse | Event Free Survival 36 months from end of therapy | R-CHOP 14 | 62 percentage of EFS at 3 years follow-up |
| R-HDS | 65 percentage of EFS at 3 years follow-up | |||
| NCT00381810 VOYAGER | Lupus Erythematosus, Systemic | Percentage of Participants With at Least 1 Serious Adverse Event Baseline to the end of the study (up to 52 weeks) | Rituximab 1000 mg | 35.5 Percentage of participants |
| NCT00422383 | Arthritis, Rheumatoid | Percentage of Participants With a Response as Determined by American College of Rheumatology (ACR) 20% Improvement (ACR20) Week 48 | Rituximab Escalated Dose + Methotrexate | 63.9 percentage of participants |
| Rituximab High Dose + Methotrexate | 72.0 percentage of participants | |||
| Rituximab Low Dose + Methotrexate | 64.2 percentage of participants | |||
| NCT00443651 SUNDIAL | Arthritis, Rheumatoid | Percentage of Patients Developing a Serious Adverse Event (SAE) Within 24 Weeks After Receiving the First Course of Rituximab Treatment From first treatment with rituximab (Day 1) through Week 24 | Rituximab 1000 mg (Stage I Patients) | 6.0 Percentage of participants |
| Rituximab 500 mg (Stage II Patients) | 9.1 Percentage of participants | |||
| NCT00486759 | Lymphoma, B-Cell | Progression-free Survival (PFS) Baseline to end of the study (up to 4 years, 4 months) | Bevacizumab + Rituximab + CHOP | 40.2 Months |
| Placebo + Rituximab + CHOP | 42.9 Months | |||
| NCT00502840 | Arthritis, Rheumatoid | Change From Baseline in DAS28 Score at Week 24 Week 24 | Rituximab Plus MTX | -2.12 scores on a scale (±1.41 Standard Deviation) |
| NCT00502996 | Arthritis, Rheumatoid | Number of Participants With AEs According to Degree of Intensity Up to Week 48 | Rituximab | 12 participants |
| Rituximab | 102 participants | |||
| Rituximab | 170 participants | |||
| Rituximab | 30 participants | |||
| NCT00502996 | Arthritis, Rheumatoid | Number of Participants With AEs Leading to Discontinuation and Any Drug Related AEs and SAEs Up to Week 48 | Rituximab | 0 participants |
| Rituximab | 2 participants | |||
| Rituximab | 97 participants | |||
| NCT00502996 | Arthritis, Rheumatoid | Number of Participants With AEs of Special Interest During the Study Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48) | Rituximab | 5 participants |
| Rituximab | 12 participants | |||
| Rituximab | 12 participants | |||
| NCT00502996 | Arthritis, Rheumatoid | Number of Participants With Any Adverse Event, Any Serious Adverse Event, and Death Up to Week 48 | Rituximab | 0 participants |
| Rituximab | 12 participants | |||
| Rituximab | 189 participants | |||
| NCT00503425 | Arthritis, Rheumatoid | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Baseline up to study withdrawal or follow-up (Approximately 104 weeks) | Rituximab | 176 Participants |
| Rituximab | 70 Participants | |||
| NCT00513747 | Leukemia, Lymphocytic, Chronic, B-Cell | Disease-Free Survival in High Risk Patients Up to 72 months | Arm A: High Risk Early Intervention | 62.7 months |
| Arm B: High Risk Observation + Later Treatment | 39.2 months | |||
| NCT00513747 | Leukemia, Lymphocytic, Chronic, B-Cell | Overall Survival (OS) for High Risk Patients Up to 72 months | Arm A: High Risk Early Intervention | NA months |
| Arm B: High Risk Observation + Later Treatment | NA months | |||
| NCT00513747 | Leukemia, Lymphocytic, Chronic, B-Cell | Time to Second Treatment in High Risk Patients Up to 72 months | Arm A: High Risk Early Intervention | 62.7 months |
| Arm B: High Risk Observation + Later Treatment | 56.3 months | |||
| NCT00562965 | Lymphoma, Follicular | Progression-Free Survival (PFS) Baseline until disease progression or death or up to 1 year after last dose of study drug | Control Regimens R-CVP + R-FND | 16.4 months |
| Rituximab + Inotuzumab Ozogamicin | NA months | |||
| NCT00577993 | Lymphoma | Number of Participants With Overall Survival (10 Years) by Treatment 10 Years | Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | 59 Participants |
| Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) | 58 Participants | |||
| NCT00578305 SCORE | Arthritis, Rheumatoid | Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24 Baseline to Week 24 | Placebo | 1.33 Units on a scale (±2.235 Standard Deviation) |
| Rituximab 1000 mg | 0.39 Units on a scale (±1.807 Standard Deviation) | |||
| Rituximab 500 mg | 0.13 Units on a scale (±2.258 Standard Deviation) | |||
| NCT00578565 | Arthritis, Rheumatoid | Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks baseline, 48 weeks | Rituximab | 4 participants |
| Rituximab | 1 participants | |||
| Rituximab | 2 participants | |||
| NCT00578565 | Arthritis, Rheumatoid | Change in Forced Vital Capacity (FVC) From Baseline to 48 Weeks baseline, 48 weeks | Rituximab | 1 participants |
| Rituximab | 2 participants | |||
| Rituximab | 4 participants | |||
| NCT00595335 | Graves Ophthalmopathy | Change in Clinical Activity Score (CAS) baseline, 6 months after the first infusion | Placebo | -1.5 units on a scale (±1.8 Standard Deviation) |
| Rituximab | -1.2 units on a scale (±2 Standard Deviation) | |||
| NCT00718549 | Leukemia, Lymphocytic, Chronic, B-Cell | Percentage of Participants With Disease Progression (PD), Relapse, or Death Due to Any Cause Assessed According to the National Cancer Institute (NCI) Revised Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) From randomization to PD, Relapse, or death due to any cause (overall approximately 5 years) | All Randomized Participants | 40.9 percentage of participants |
| Maintenance Arm: Rituximab | 27.3 percentage of participants | |||
| Observation Arm: No Intervention | 54.5 percentage of participants | |||
| NCT00718549 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-Fee Survival (PFS) Assessed According to the NCI Revised Guidelines for the Diagnosis and Treatment of CLL From randomization to PD, relapse, or death due to any cause (overall approximately 5 years) | All Randomized Participants | 3.1 years |
| Maintenance Arm: Rituximab | NA years | |||
| Observation Arm: No Intervention | 2.1 years | |||
| NCT00719472 RATE | Lymphoma, Non-Hodgkin | Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2 Days 1 and 2 of Cycle 2 | Rituximab 375 mg/m^2 | 1.1 Percentage of participants |
| NCT00722137 | Lymphoma, Mantle-Cell | Progression Free Survival (PFS) Median duration of follow-up of 40 months | R-CHOP | 437.0 Days |
| VcR-CAP | 751.0 Days | |||
| NCT00770562 | Purpura, Thrombocytopenic, Idiopathic | Percentage of Participants With a Sustained Response Week 24 | Arm A: Dexamethasone | 36 percentage of participants |
| Arm B: Dexamethasone + Rituximab | 63 percentage of participants | |||
| NCT00774202 | Purpura, Thrombocytopenic, Idiopathic | Efficacy of Higher Double Doses of Rituxan and of Standard Dose of Rituxan + Cyclophosphamide, Vincristine, Prednisone 2 years | Double Dose of Rituximab | 7 Participants |
| Double Dose of Rituximab | 0 Participants | |||
| Double Dose of Rituximab | 1 Participants | |||
| Standard Dose of Rituxan Plus CVP (R-CVP) | 8 Participants | |||
| Standard Dose of Rituxan Plus CVP (R-CVP) | 0 Participants | |||
| Standard Dose of Rituxan Plus CVP (R-CVP) | 1 Participants | |||
| NCT00877006 | Lymphoma, Non-Hodgkin | Percentage of Participants With Complete Response (CR) at End of Treatment Period 6 to 8 21 or 28-day cycles (18-32 weeks) | Bendamustine and Rituximab (BR) | 31 percentage of participants |
| R-CHOP/R-CVP | 25 percentage of participants | |||
| NCT01010061 | Leukemia, Lymphocytic, Chronic, B-Cell | Percentage of Participants With Progression Free Survival Events Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization) | Chlorambucil (Clb) | 90.7 Percentage of participants |
| Obinutuzumab + Chlorambucil (GClb) | 72.7 Percentage of participants | |||
| NCT01010061 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization) | Chlorambucil (Clb) | 11.1 Months |
| Obinutuzumab + Chlorambucil (GClb) | 31.1 Months | |||
| NCT01014208 ORCHARRD | Lymphoma, Large B-Cell, Diffuse | Progression-free Survival as Assessed by Independent Reviewers From randomization until the date of stable disease after two cycles of salvage chemotherapy, progression, or death (assessed for up to 5 years) | Ofatumumab + Chemotherapy | 1.81 Months |
| Rituximab + Chemotherapy | 2.14 Months | |||
| NCT01073163 | Lymphoma, Non-Hodgkin | Mean Change From Baseline in QT Interval as Corrected by the Fridericia Method (QTcF) at End of Infusion Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion. | Bendamustine With Rituximab | 410.4 milliseconds (ms) (±23.6 Standard Deviation) |
| Bendamustine With Rituximab | 6.7 milliseconds (ms) (±10.3 Standard Deviation) | |||
| NCT01126541 | Arthritis, Rheumatoid | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104 Week 104 | Randomized Retreatment Arm A: Rituximab 1000 mg | 2761.4 score on a scale*week (±507.8 Standard Error) |
| Randomized Retreatment Arm B: Rituximab 1000 mg x 2 | 2666.0 score on a scale*week (±490.4 Standard Error) | |||
| NCT01144364 | Lymphoma, Non-Hodgkin | Percentage of Participants With Disease Progression or Death 12, 24, and 34 months | Rituximab Induction, Observation Maintenance | 34.7 percentage of participants |
| Rituximab Induction, Rituximab Maintenance | 29.7 percentage of participants | |||
| NCT01144364 | Lymphoma, Non-Hodgkin | PFS Randomization- Percentage of Participants Estimated to be Free of Progression at 12, 24, and 34 Months 12, 24, and 34 months | Rituximab Induction, Observation Maintenance | 62.3 percentage of participants |
| Rituximab Induction, Observation Maintenance | 82.5 percentage of participants | |||
| Rituximab Induction, Observation Maintenance | 68.9 percentage of participants | |||
| Rituximab Induction, Rituximab Maintenance | 92.0 percentage of participants | |||
| Rituximab Induction, Rituximab Maintenance | 70.4 percentage of participants | |||
| Rituximab Induction, Rituximab Maintenance | 81.0 percentage of participants | |||
| NCT01164098 | Proteinuria | Maximum of the Urine Protein/Creatinine Ratio Observed Between Post-Transplant Days 3-30. between post-transplant day 3 and day 30 | No Rituximab | 2.85 ratio (±1.52 Standard Error) |
| Rituximab | 1.44 ratio (±1.33 Standard Error) | |||
| NCT01180036 MENTOR | Glomerulonephritis, Membranous | Remission Status 24 months after randomization | Cyclosporine Treatment Arm | 34 Participants |
| Cyclosporine Treatment Arm | 13 Participants | |||
| Rituximab Treatment Arm | 39 Participants | |||
| Rituximab Treatment Arm | 39 Participants | |||
| NCT01197560 | Lymphoma, Large B-Cell, Diffuse | Stage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 and Evaluated by the Independent Response Adjudication Committee (IRAC) From the date of randomization to the data cut-off of 4 July 2013; when all patients reached the scheduled 16-week assessment or had progressed/died before the scheduled 16-week assessment); the median study duration was 27.0 and 19.7 weeks, respectively. | Investigators Choice (IC) | 11.8 percentage of participants |
| Investigators Choice (IC) | 12.0 percentage of participants | |||
| Investigators Choice (IC) | 11.5 percentage of participants | |||
| Lenalidomide | 28.6 percentage of participants | |||
| Lenalidomide | 26.1 percentage of participants | |||
| Lenalidomide | 27.5 percentage of participants | |||
| NCT01197560 | Lymphoma, Large B-Cell, Diffuse | Stage 1: Percentage of Participants With an Overall Response According to the IWG Response Criteria Based on the Investigators Assessment at the Final Data Cut During the Core Treatment Phase From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively. | Investigators Choice (IC) | 13.7 Percentage of participants |
| Lenalidomide | 29.4 Percentage of participants | |||
| NCT01200589 HOMER | Lymphoma, Non-Hodgkin | Progression-free Survival (PFS) - Number of Participants With PFS Events 200 weeks | Ofatumumab | 114 Participants |
| Rituximab | 117 Participants | |||
| NCT01200758 | Lymphoma, Non-Hodgkin | Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours predose on Cy8) of induction treatment (1 Cy=3 weeks) | Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) | 83.1 micrograms per milliliter (mcg/mL) (±36.7 Geometric Coefficient of Variation) |
| Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) | 134.6 micrograms per milliliter (mcg/mL) (±43.2 Geometric Coefficient of Variation) | |||
| NCT01200758 | Lymphoma, Non-Hodgkin | Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL) Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks) | Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) | 85.1 percentage of participants |
| Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) | 80.3 percentage of participants | |||
| NCT01232556 | Lymphoma, Large B-Cell, Diffuse | Overall Survival From randomization up to 5 years after last dose or up to final study visit, whichever occurs first. | Inotuzumab Ozogamicin+Rituximab | 9.5 Months |
| Rituximab+Gemcitabine or Rituximab+Bendamustine | 9.5 Months | |||
| NCT01232556 | Lymphoma, Large B-Cell, Diffuse | Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population) Up to 20 weeks after the first dose of study drug | Inotuzumab Ozogamicin+Rituximab | 14.6 Percentage of Participants |
| Inotuzumab Ozogamicin+Rituximab | 25.0 Percentage of Participants | |||
| Inotuzumab Ozogamicin+Rituximab | 27.4 Percentage of Participants | |||
| Inotuzumab Ozogamicin+Rituximab | 37.2 Percentage of Participants | |||
| Inotuzumab Ozogamicin+Rituximab | 98.8 Percentage of Participants | |||
| Inotuzumab Ozogamicin+Rituximab | 79.9 Percentage of Participants | |||
| Inotuzumab Ozogamicin+Rituximab | 31.1 Percentage of Participants | |||
| Rituximab+Gemcitabine or Rituximab+Bendamustine | 100.0 Percentage of Participants | |||
| Rituximab+Gemcitabine or Rituximab+Bendamustine | 37.7 Percentage of Participants | |||
| Rituximab+Gemcitabine or Rituximab+Bendamustine | 13.8 Percentage of Participants | |||
| Rituximab+Gemcitabine or Rituximab+Bendamustine | 79.6 Percentage of Participants | |||
| Rituximab+Gemcitabine or Rituximab+Bendamustine | 46.1 Percentage of Participants | |||
| Rituximab+Gemcitabine or Rituximab+Bendamustine | 29.3 Percentage of Participants | |||
| Rituximab+Gemcitabine or Rituximab+Bendamustine | 18.0 Percentage of Participants | |||
| NCT01272908 | Arthritis, Rheumatoid | Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary Days 1, 2, 15, and 16 and Week 48 of Initial treatment period | Initial Treatment Period: Rituximab + MTX | 20.8 percentage of participants |
| Initial Treatment Period: Rituximab + MTX | 4.2 percentage of participants | |||
| Initial Treatment Period: Rituximab + MTX | 10.0 percentage of participants | |||
| Initial Treatment Period: Rituximab + MTX | 47.5 percentage of participants | |||
| Initial Treatment Period: Rituximab + MTX | 0 percentage of participants | |||
| Initial Treatment Period: Rituximab + MTX | 2.5 percentage of participants | |||
| Initial Treatment Period: Rituximab + MTX | 85.0 percentage of participants | |||
| Initial Treatment Period: Rituximab + MTX | 41.7 percentage of participants | |||
| NCT01287741 | Lymphoma, Large B-Cell, Diffuse | Median Time to Progression-Free Survival (PFS), Investigator-Assessed Baseline up to approximately 6.5 years (up to 31 January 2018) | Obinutuzumab+Chemotherapy | 68.3 months |
| Rituximab+Chemotherapy | 74.5 months | |||
| NCT01321541 PIX-R | Lymphoma, Large B-Cell, Diffuse | Progression Free Survival (PFS) From the date of randomization to the date of progressive disease or death due to any cause (whichever is first reported) (Up to 100 weeks) | Gemcitabine + Rituximab | 6.3 Months |
| Pixantrone + Rituximab | 7.3 Months | |||
| NCT01332968 | Lymphoma, Non-Hodgkin | Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed Baseline up to data cut-off (up to approximately 4 years and 7 months) | Obinutuzumab+Chemotherapy | 34.3 percentage of participants with event |
| Obinutuzumab+Chemotherapy | 16.8 percentage of participants with event | |||
| Rituximab+Chemotherapy | 24.0 percentage of participants with event | |||
| Rituximab+Chemotherapy | 40.6 percentage of participants with event | |||
| NCT01332994 | Arthritis, Rheumatoid | Percentage of Participants Achieving Remission at Week 16 According to DAS28 Week 16 | TCZ/TCZ or TCZ/RTX | 42.8 percentage of participants |
| NCT01419665 ASSIST_FL | Lymphoma, Follicular | Overall Response Rate (ORR) 24 weeks | GP2013 | 87.1 percentage |
| Rituximab | 87.5 percentage | |||
| NCT01461928 MabCute | Lymphoma, Non-Hodgkin | Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia From randomization (Maintenance II) up to disease progression or death, whichever occurs first (up to approximately 24 months) | Maintenance II - Arm A (Rituximab) | NA Months |
| Maintenance II - Arm B (Observation Only) | NA Months | |||
| NCT01476787 RELEVANCE | Lymphoma, Follicular | Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review At 120 weeks | Investigator Choice | 53.0 Percent of participants |
| Rituximab-Lenalidomide | 48.1 Percent of participants | |||
| NCT01476787 RELEVANCE | Lymphoma, Follicular | Progression-free Survival (PFS) From randomization into the study to the first observation of documented disease progression or death due to any cause (up to approximately 140 months). | Investigator Choice | 123.8 Months |
| Rituximab-Lenalidomide | 120.2 Months | |||
| NCT01510184 | Lymphoma, Large B-Cell, Diffuse | Overall Survival (OS) for Living Participants From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years) | Observation | 6.14 months |
| Zevalin | 8.90 months | |||
| NCT01510184 | Lymphoma, Large B-Cell, Diffuse | Overall Survival for Death From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years) | Observation | 5.82 months |
| Zevalin | 16.76 months | |||
| NCT01539512 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-Free Survival Up to 17 months | Idelalisib + Rituximab | NA months |
| Placebo + Rituximab | 5.5 months | |||
| NCT01569295 Tugela | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-Free Survival (PFS) Up to 84 months | Idelalisib + Bendamustine + Rituximab | 21.8 months |
| Placebo + Bendamustine + Rituximab | 11.1 months | |||
| NCT01609010 | Lymphoma | Treatment Failure - Percentage of Participants With an Event Baseline (BL), Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period | Rituximab + IFN | 67 percentage of participants |
| Rituximab Monotherapy | 68 percentage of participants | |||
| NCT01609010 | Lymphoma | Treatment Failure - Time to Event BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period | Rituximab + IFN | 28.0 months |
| Rituximab Monotherapy | 21.5 months | |||
| NCT01611090 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) Up to 5 years | Ibrutinib+BR | 65.12 Months |
| Placebo+BR | 14.32 Months | |||
| NCT01649856 | Lymphoma, Large B-Cell, Diffuse | Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu) Up to approximately 4.25 years | Rituximab IV | 42.4 percentage of participants |
| Rituximab SC | 50.6 percentage of participants | |||
| NCT01697267 RITAZAREM | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Relapse-free Survival Any patients who have not relapsed at up to a maximum of 4 years will be censored. | Azathioprine Maintenance | 32 participants |
| Azathioprine Maintenance | 28 participants | |||
| Azathioprine Maintenance | 60 participants | |||
| Rituximab Maintenance | 13 participants | |||
| Rituximab Maintenance | 38 participants | |||
| Rituximab Maintenance | 25 participants | |||
| NCT01724021 | Lymphoma, Large B-Cell, Diffuse | Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 Cycle 6 (Up to 24 weeks) | Arm A | 79.1 percentage of participants |
| Arm B | 80.6 percentage of participants | |||
| NCT01724021 | Lymphoma, Large B-Cell, Diffuse | Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8 Cycle 8 (Up to 32 weeks) | Arm A | 77.1 percentage of participants |
| Arm B | 84.2 percentage of participants | |||
| NCT01776840 | Lymphoma, Mantle-Cell | Progression-free Survival (PFS) Up to 97 months | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) | 80.6 months |
| Placebo + Bendamustine and Rituximab (BR) (Treatment A) | 52.9 months | |||
| NCT01855750 | Lymphoma, Large B-Cell, Diffuse | Event-Free Survival (EFS) - Activated B-Cell (ABC) Population Up to approximately 4.5 years | Treatment Arm A: Placebo+R-CHOP | 48.16 Months |
| Treatment Arm B: Ibrutinib+R-CHOP | 48.56 Months | |||
| NCT01855750 | Lymphoma, Large B-Cell, Diffuse | Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population Up to 5.5 years | Treatment Arm A: Placebo+R-CHOP | 54.77 Months |
| Treatment Arm B: Ibrutinib+R-CHOP | 49.64 Months | |||
| NCT01886872 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression Free Survival (PFS) Time from study entry to the time of documented disease progression or death. The analysis was event driven, performed at 2.5 years after the last patient enrolled;up to 4 years. | Arm A (Rituximab, Bendamustine Hydrochloride) | 43 months |
| Arm B (Ibrutinib) | NA months | |||
| Arm C (Ibrutinib, Rituximab) | NA months | |||
| NCT01889069 | Lymphoma | Percentage of Participants With Administration-Associated Reactions (AAR) Baseline up to 54 months | Diffuse Large B-Cell Lymphoma (DLBCL) | 4.2 Percentage of Participants |
| Diffuse Large B-Cell Lymphoma (DLBCL) | 2.8 Percentage of Participants | |||
| Diffuse Large B-Cell Lymphoma (DLBCL) | 1.4 Percentage of Participants | |||
| Diffuse Large B-Cell Lymphoma (DLBCL) | 0 Percentage of Participants | |||
| Follicular Lymphoma (FL) | 0 Percentage of Participants | |||
| Follicular Lymphoma (FL) | 0 Percentage of Participants | |||
| Follicular Lymphoma (FL) | 8.1 Percentage of Participants | |||
| Follicular Lymphoma (FL) | 8.1 Percentage of Participants | |||
| Subcutaneous (SC) Rituximab | 0 Percentage of Participants | |||
| Subcutaneous (SC) Rituximab | 5.1 Percentage of Participants | |||
| Subcutaneous (SC) Rituximab | 1.3 Percentage of Participants | |||
| Subcutaneous (SC) Rituximab | 6.3 Percentage of Participants | |||
| NCT01938001 AUGMENT | Lymphoma, Non-Hodgkin | Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC) From randomization of study drug up to disease progression or death, which occurred first; up to the data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months). | Rituximab + Lenalidomide (R^2) | 39.4 months |
| Rituximab + Placebo | 14.1 months | |||
| NCT01973387 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) From the date of randomization to the date of disease progression or death, whichever was first reported (Up to 3.7 years) | Ibrutinib | NA months |
| Rituximab | 8.38 months | |||
| NCT01974440 SELENE | Lymphoma | Primary Analysis: Progression Free Survival (PFS): Stratified Analysis Up to 8 years | Ibrutinib + CIT | 40.51 months |
| Placebo + Chemoimmunotherapy (CIT) | 23.75 months | |||
| NCT01974440 SELENE | Lymphoma | Supplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL) Up to 8 years | Ibrutinib + CIT | NA months |
| Placebo + Chemoimmunotherapy (CIT) | 91.63 months | |||
| NCT01980888 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-Free Survival Up to 22 months | Idelalisib+Bendamustine+Rituximab | NA months |
| Placebo+Bendamustine+Rituximab | NA months | |||
| NCT01987505 | Lymphoma, Non-Hodgkin | Percentage of Participants With Administration-Associated Reactions (AARs) From start of treatment to end of treatment (up to 32 months) | Diffuse Large B-Cell Lymphoma (DLBCL) | 0 percentage of participants |
| Diffuse Large B-Cell Lymphoma (DLBCL) | 57.9 percentage of participants | |||
| Diffuse Large B-Cell Lymphoma (DLBCL) | 34.5 percentage of participants | |||
| Diffuse Large B-Cell Lymphoma (DLBCL) | 42.1 percentage of participants | |||
| Diffuse Large B-Cell Lymphoma (DLBCL) | 0 percentage of participants | |||
| Follicular Lymphoma (FL) | 1.8 percentage of participants | |||
| Follicular Lymphoma (FL) | 52.3 percentage of participants | |||
| Follicular Lymphoma (FL) | 2.7 percentage of participants | |||
| Follicular Lymphoma (FL) | 11.1 percentage of participants | |||
| Follicular Lymphoma (FL) | 88.9 percentage of participants | |||
| Subcutaneous Rituximab | 15.1 percentage of participants | |||
| Subcutaneous Rituximab | 1.4 percentage of participants | |||
| Subcutaneous Rituximab | 84.9 percentage of participants | |||
| Subcutaneous Rituximab | 48.6 percentage of participants | |||
| Subcutaneous Rituximab | 2.1 percentage of participants | |||
| NCT01996865 MAGNIFY | Lymphoma | Progression Free Survival (PFS) From the first dose date of maintenance therapy to objective disease progression or death from any cause, whichever occurs first (up to approximately 432 weeks) | Arm A: Lenalidomide + Rituximab | 263.1 Weeks |
| Arm B: Rituximab | 229.1 Weeks | |||
| NCT01998880 | Leukemia, Lymphocytic, Chronic, B-Cell | Percentage of Participants With Progression Free Survival Events Randomization to clinical cutoff (median observation 57.7 months) | Chlorambucil (Clb) | 90.7 Percentage of participants |
| Rituximab + Chlorambucil (RClb) | 90.1 Percentage of participants | |||
| NCT01998880 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) Randomization to clinical cutoff (median observation 57.7 months) | Chlorambucil (Clb) | 11.1 Months |
| Rituximab + Chlorambucil (RClb) | 16.5 Months | |||
| NCT02003222 | Burkitt Lymphoma | Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years | MRD Negative - Blinatumomab + Chemotherapy | NA months |
| MRD Negative - Chemotherapy | NA months | |||
| NCT02005471 MURANO | Leukemia, Lymphocytic, Chronic, B-Cell | Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months) | Bendamustine + Rituximab Main Study | 88.7 percentage of participants |
| Venetoclax + Rituximab Main Study | 70.1 percentage of participants | |||
| NCT02005471 MURANO | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months) | Bendamustine + Rituximab Main Study | 17.0 months |
| Venetoclax + Rituximab Main Study | 54.7 months | |||
| NCT02006706 | Arthritis, Rheumatoid | Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24 Baseline, Week 24 | Rituximab/Methylprednisolone/MTX | 2.98 score on a scale (±1.80 Standard Deviation) |
| NCT02048813 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) Rate at 3 Years Assessed every 3 months until progression up to 4 years and 8 months | Arm A (Ibrutinib, Rituximab) | 0.894 Proportion of participants |
| Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 0.729 Proportion of participants | |||
| NCT02053610 | Leukemia, Lymphocytic, Chronic, B-Cell | Percentage of Participants With Progression Free Survival Events Randomization to clinical cutoff (median observation 59.4 months) | Obinutuzumab + Chlorambucil (GClb) | 73.3 percentage of participants |
| Rituximab + Chlorambucil (RClb) | 88.5 percentage of participants | |||
| NCT02053610 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) Randomization to clinical cutoff (median observation 59.4 months) | Obinutuzumab + Chlorambucil (GClb) | 28.9 months |
| Rituximab + Chlorambucil (RClb) | 15.7 months | |||
| NCT02079532 | Arthritis, Rheumatoid | Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28) Week 24 | Rituximab + MTX | -1.56 scores on a scale (±1.40 Standard Deviation) |
| NCT02097745 | Arthritis, Rheumatoid | Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response Baseline to the end of the retreatment period (up to 7 years, 6 months) | Rituximab | 72.8 Percentage of participants |
| Rituximab | 74.9 Percentage of participants | |||
| Rituximab | 73.9 Percentage of participants | |||
| Rituximab | 67.4 Percentage of participants | |||
| Rituximab | 69.9 Percentage of participants | |||
| Rituximab | 67.5 Percentage of participants | |||
| NCT02165397 | Lymphoma | Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54 Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr]) | Ibrutinib + Rituximab | 68.0 percentage of participants |
| Open-Label Substudy: Ibrutinib | 39.7 percentage of participants | |||
| Placebo + Rituximab | 25.3 percentage of participants | |||
| NCT02285062 ROBUST | Lymphoma, Large B-Cell, Diffuse | Kaplan-Meier Estimate of Progression Free Survival (PFS) From the date of randomization up to the data cut off date of 15 March 2019; median follow-up of 24.5 months | Lenalidomide Plus R-CHOP (R2-CHOP) | NA months |
| Placebo Plus R-CHOP | NA months | |||
| NCT02320292 | — | Complete Response (CR) Rate at the 6-month Disease Assessment 6 months | Arm A (Rituximab) | 3 Participants |
| Arm A (Rituximab) | 6 Participants | |||
| Arm A (Rituximab) | 1 Participants | |||
| Arm B (Rituximab, Yttrium Y-90 Ibritumomab Tiuxetan) | 2 Participants | |||
| Arm B (Rituximab, Yttrium Y-90 Ibritumomab Tiuxetan) | 6 Participants | |||
| Arm B (Rituximab, Yttrium Y-90 Ibritumomab Tiuxetan) | 2 Participants | |||
| NCT02367040 CHRONOS-3 | Lymphoma, Non-Hodgkin | Progression Free Survival (PFS) Based on Independent Central Review. From first participant randomization (20-Aug-2015) up to data cut-off at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years and final analysis at 15-Nov-2024 up to 9 years | Copanlisib + Rituximab | 21.5 Months |
| Copanlisib + Rituximab | 23.2 Months | |||
| Copanlisib + Rituximab | 22.4 Months | |||
| Placebo + Rituximab | 14.0 Months | |||
| Placebo + Rituximab | 13.8 Months | |||
| Placebo + Rituximab | 13.8 Months | |||
| NCT02383589 | Pemphigus | Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI) Activity Score From Baseline up to 52 Weeks (up to clinical cut-off date (CCOD) of 28 November 2018) | Mycophenolate Mofetil (MMF) | 9.5 Percentage of Participants |
| Rituximab (RTX) | 40.3 Percentage of Participants | |||
| NCT02406092 | Lymphoma, Non-Hodgkin | Percentage of Participants With Administration-Associated Reactions (AARs) Within 24 hours of each rituximab SC administration (maximum treatment duration up to 32 months for FL participants and up to 8 months for DLBCL participants) | DLBCL Arm | 2.1 Percentage of Participants % |
| DLBCL Arm | 1.1 Percentage of Participants % | |||
| DLBCL Arm | 1.1 Percentage of Participants % | |||
| DLBCL Arm | 2.1 Percentage of Participants % | |||
| DLBCL Arm | 4.2 Percentage of Participants % | |||
| DLBCL Arm | 4.2 Percentage of Participants % | |||
| DLBCL Arm | 1.1 Percentage of Participants % | |||
| DLBCL Arm | 1.1 Percentage of Participants % | |||
| DLBCL Arm | 1.1 Percentage of Participants % | |||
| FL Arm | 0 Percentage of Participants % | |||
| FL Arm | 0 Percentage of Participants % | |||
| FL Arm | 3.7 Percentage of Participants % | |||
| FL Arm | 7.4 Percentage of Participants % | |||
| FL Arm | 0 Percentage of Participants % | |||
| FL Arm | 0 Percentage of Participants % | |||
| FL Arm | 0 Percentage of Participants % | |||
| FL Arm | 0 Percentage of Participants % | |||
| FL Arm | 0 Percentage of Participants % | |||
| Overall Population | 4.9 Percentage of Participants % | |||
| Overall Population | 0.8 Percentage of Participants % | |||
| Overall Population | 1.6 Percentage of Participants % | |||
| Overall Population | 0.8 Percentage of Participants % | |||
| Overall Population | 0.8 Percentage of Participants % | |||
| Overall Population | 1.6 Percentage of Participants % | |||
| Overall Population | 0.8 Percentage of Participants % | |||
| Overall Population | 1.6 Percentage of Participants % | |||
| Overall Population | 3.3 Percentage of Participants % | |||
| NCT02417129 | Lymphoma, Non-Hodgkin | Overall Response Measured as Overall Response Rate (ORR) at Week 30 for BI 695500 Versus Rituximab From first administration of study medication until 30 weeks thereafter. | BI 695500 | 1 participants |
| BI 695500 | 0 participants | |||
| NCT02514772 ASSIST-RT | Arthritis, Rheumatoid | Immunogenicity 24 weeks study duration | GP2013 | 0 Participants |
| Rituxan® / MabThera® | 1 Participants | |||
| NCT02514772 ASSIST-RT | Arthritis, Rheumatoid | Number of Patients Experiencing Anaphylactic Reactions Within 24 hours of each study drug infusion: on Day 1 and Day 14 | GP2013 | 0 Participants |
| Rituxan® / MabThera® | 1 Participants | |||
| NCT02514772 ASSIST-RT | Arthritis, Rheumatoid | Number of Patients Experiencing Hypersensitivity Reactions 24 weeks study duration | GP2013 | 5 Participants |
| Rituxan® / MabThera® | 6 Participants | |||
| NCT02514772 ASSIST-RT | Arthritis, Rheumatoid | Number of Patients Experiencing Potential Infusion-Related Reactions On the day of and on the day after each study drug infusion (e.g. on study day 1 and 2 for the 1st study drug infusion and on study day 14 and 15 for the 2nd study drug infusion, if the second drug infusion was given on study day 14) | GP2013 | 2 Participants |
| GP2013 | 4 Participants | |||
| GP2013 | 6 Participants | |||
| Rituxan ® / MabThera ® | 10 Participants | |||
| Rituxan ® / MabThera ® | 7 Participants | |||
| Rituxan ® / MabThera ® | 5 Participants | |||
| NCT02569996 | Lymphoma, Follicular | Event-free Survival From randomization to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first, assessed up to 5 years | Rituximab | 53.944 months |
| NCT02617485 MADILYM | Lymphoma, Large B-Cell, Diffuse | Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4]) Baseline to Week 4 | MabionCD20 | 1559.51 (μg*day)/mL (±358.092 Standard Deviation) |
| MabThera | 1509.79 (μg*day)/mL (±382.559 Standard Deviation) | |||
| NCT02617485 MADILYM | Lymphoma, Large B-Cell, Diffuse | Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26]) Week 13 to Week 26 | MabionCD20 | 16498.9 (μg*day)/mL (±3492.39 Standard Deviation) |
| MabThera | 15647.4 (μg*day)/mL (±3629.83 Standard Deviation) | |||
| NCT02626455 CHRONOS-4 | Lymphoma, Non-Hodgkin | Phase 3: Progression-free Survival (PFS) by Independent Central Review Approximately 6 years 4 months | Phase 3: Copa+R-B/R-CHOP | 32.9 Months |
| Phase 3: Pbo+R-B/R-CHOP | 33.3 Months | |||
| NCT02626455 CHRONOS-4 | Lymphoma, Non-Hodgkin | SRI: Occurrence of Dose-limiting Toxicities (DLT) At Cycle 1: 28 days for Copa+R-B or 21 days for Copa+R-CHOP | SRI: Copa+R-B 45 mg | 0 Percentage |
| SRI: Copa+R-B 60 mg (Excluding Subjects From Japan) | 0 Percentage | |||
| SRI: Copa+R-CHOP 45 mg | 0 Percentage | |||
| SRI: Copa+R-CHOP 60 mg | 0 Percentage | |||
| SRI: Japan Copa+R-B 60 mg | 16.7 Percentage | |||
| NCT02703272 | Lymphoma, Non-Hodgkin | Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib Up to Cycle 3 (each cycle of 21 or 28 days) | Part 1: Ibrutinib: 240 mg/m^2 | 348 milliliter per hour (mL/h) |
| Part 1: Ibrutinib: 240 mg/m^2 | 1450 milliliter per hour (mL/h) | |||
| Part 1: Ibrutinib: 240 mg/m^2 | 1220 milliliter per hour (mL/h) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 729 milliliter per hour (mL/h) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 805 milliliter per hour (mL/h) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 508 milliliter per hour (mL/h) | |||
| Part 1: Ibrutinib: 440 mg/m^2 | 1200 milliliter per hour (mL/h) | |||
| Part 1: Ibrutinib: 440 mg/m^2 | 1300 milliliter per hour (mL/h) | |||
| NCT02703272 | Lymphoma, Non-Hodgkin | Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib Up to Cycle 3 (each cycle of 21 or 28 days) | Part 1: Ibrutinib: 240 mg/m^2 | 18 liter(s) |
| Part 1: Ibrutinib: 240 mg/m^2 | 11.1 liter(s) | |||
| Part 1: Ibrutinib: 240 mg/m^2 | 3.63 liter(s) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 11.3 liter(s) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 7.55 liter(s) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 5.18 liter(s) | |||
| Part 1: Ibrutinib: 440 mg/m^2 | 19 liter(s) | |||
| Part 1: Ibrutinib: 440 mg/m^2 | 7.63 liter(s) | |||
| NCT02703272 | Lymphoma, Non-Hodgkin | Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib Up to Cycle 3 (each cycle of 21 or 28 days) | Part 1: Ibrutinib: 240 mg/m^2 | 145 hours*nanogram per milliliter (h*ng/mL) |
| Part 1: Ibrutinib: 240 mg/m^2 | 1210 hours*nanogram per milliliter (h*ng/mL) | |||
| Part 1: Ibrutinib: 240 mg/m^2 | 143 hours*nanogram per milliliter (h*ng/mL) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 349 hours*nanogram per milliliter (h*ng/mL) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 661 hours*nanogram per milliliter (h*ng/mL) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 386 hours*nanogram per milliliter (h*ng/mL) | |||
| Part 1: Ibrutinib: 440 mg/m^2 | 324 hours*nanogram per milliliter (h*ng/mL) | |||
| Part 1: Ibrutinib: 440 mg/m^2 | 310 hours*nanogram per milliliter (h*ng/mL) | |||
| NCT02703272 | Lymphoma, Non-Hodgkin | Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib Up to Cycle 3 (each cycle of 21 or 28 days) | Part 1: Ibrutinib: 240 mg/m^2 | 3.86 nanograms per milliliter (ng/mL) |
| Part 1: Ibrutinib: 240 mg/m^2 | 3.46 nanograms per milliliter (ng/mL) | |||
| Part 1: Ibrutinib: 240 mg/m^2 | 4.88 nanograms per milliliter (ng/mL) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 3.64 nanograms per milliliter (ng/mL) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 4.73 nanograms per milliliter (ng/mL) | |||
| Part 1: Ibrutinib: 329 mg/m^2 | 4.48 nanograms per milliliter (ng/mL) | |||
| Part 1: Ibrutinib: 440 mg/m^2 | 5.07 nanograms per milliliter (ng/mL) | |||
| Part 1: Ibrutinib: 440 mg/m^2 | 3.88 nanograms per milliliter (ng/mL) | |||
| NCT02703272 | Lymphoma, Non-Hodgkin | Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups Time from Randomization to death, disease progression, or lack of CR or PR after 3 cycles of treatment (up to 4 year and 4 months) | Part 2: Chemoimmunotherapy | 6.97 Months |
| Part 2: Ibrutinib+CIT (RICE or RVICI) | 6.05 Months | |||
| NCT02747043 JASMINE | Lymphoma, Non-Hodgkin | Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of Disease Post treatment up to Week 28 | ABP 798 | 78.0 percentage of participants |
| Rituximab | 70.2 percentage of participants | |||
| NCT02763319 B-MIND | Lymphoma, Large B-Cell, Diffuse | Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Natural Killer Cell Count-Low Subgroup up to 46.5 months | Rituximab + Bendamustine | 5.60 months |
| Tafasitamab + Bendamustine | 5.60 months | |||
| NCT02763319 B-MIND | Lymphoma, Large B-Cell, Diffuse | Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall Population up to 41.4 months | Rituximab + Bendamustine | 8.30 months |
| Tafasitamab + Bendamustine | 7.10 months | |||
| NCT02792699 | Arthritis, Rheumatoid | Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) After the Second Infusion of the First Dose Day 15, pre-dose, end of infusion, and 3, 6, 24, and 48 hours, and 2, 6, and 10 weeks postdose. | ABP 798 | 149398 h*µg/mL (±36.2 Geometric Coefficient of Variation) |
| Rituximab (EU) | 172463 h*µg/mL (±32.9 Geometric Coefficient of Variation) | |||
| Rituximab (US) | 158529 h*µg/mL (±34.9 Geometric Coefficient of Variation) | |||
| NCT02792699 | Arthritis, Rheumatoid | Maximum Observed Drug Concentration (Cmax) After the Second Infusion of the First Dose Day 15, pre-dose, end of infusion, and 3, 6, 24, and 48 hours, and 2, 6, and 10 weeks postdose. | ABP 798 | 361 µg/mL (±23.5 Geometric Coefficient of Variation) |
| Rituximab (EU) | 394 µg/mL (±22.0 Geometric Coefficient of Variation) | |||
| Rituximab (US) | 372 µg/mL (±24.7 Geometric Coefficient of Variation) | |||
| NCT02947347 | Lymphoma, Non-Hodgkin | Progression-Free Survival (PFS) as Assessed by Investigator Primary Analysis cut-off; median overall follow-up of 53.75 months | Arm A: Ibrutinib + Rituximab | 42.02 months |
| Arm B: Placebo + Rituximab | 32.76 months | |||
| NCT02950155 Rinomax | Myasthenia Gravis | Percentage of Patients With Quantitative MG Score (QMG) Score ≤ 4 and a Daily Prednisolon Dose of ≤ 10mg at 16 Weeks After Administration of Study Drug/Placebo. 16 weeks | Rituximab | 17 Participants |
| Sodium Chloride Solution | 6 Participants | |||
| NCT02951156 Javelin DLBCL | Lymphoma, Large B-Cell, Diffuse | Number of Participants With Dose Limiting Toxicities (DLT) Day 1 Cycle 1 up to 4 Weeks | Avelumab+Azacitidine+Utomilumab | 0 Participants |
| Avelumab+Bendamustine+Rituximab | 0 Participants | |||
| Avelumab+Rituximab+Utomilumab | 1 Participants | |||
| NCT02951156 Javelin DLBCL | Lymphoma, Large B-Cell, Diffuse | Objective Response Rate (ORR) as Assessed by Investigator Per Lugano Response Classification Criteria Randomization until date of PD, start of new anticancer therapy, discontinuation from study or death due to any cause, whichever occurred first (maximum up to 36 months) | Avelumab+Azacitidine+Utomilumab | 0 Percentage of participants |
| Avelumab+Bendamustine+Rituximab | 27.3 Percentage of participants | |||
| Avelumab+Rituximab+Utomilumab | 11.1 Percentage of participants | |||
| NCT02970318 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up | Arm A: Acalabrutinib Monotherapy | NA Months |
| Arm B: Investigators Choice | 16.5 Months | |||
| NCT02980042 | Multiple Sclerosis | Difference in the Total Number of IRRs After Each Infusion of Ocrelizumab Compared to Rituximab Infusions in the Comparator Group. Pre-study (Enrollment), Day 1, Day 15, Week 24 | Comparator Group | 28 Infusions |
| Switching Group | 4 Infusions | |||
| Switching Group | 14 Infusions | |||
| Switching Group | 12 Infusions | |||
| NCT02980042 | Multiple Sclerosis | Proportion of Infusions With >= 1 IRR Between the Switching and Comparator Groups Day 1, Day 15, Week 24 | Comparator Group | 14 percentage of infusions with IRRs |
| Switching Group | 10 percentage of infusions with IRRs | |||
| NCT02980042 | Multiple Sclerosis | Proportion of Patients With an IRR at Day 1 Versus Day 15 and Week 24 Infusions Day 1, Day 15, Week 24 | Switching Group - Day 1 Infusion | 14 Participants |
| Switching Group - Day 15 Infusion | 4 Participants | |||
| Switching Group - Week 24 Infusion | 12 Participants | |||
| NCT02980042 | Multiple Sclerosis | Severity of IRRs Following the Day 1 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions Day 1, pre-study infusions | Comparator Group | 172 Infusions |
| Comparator Group | 0 Infusions | |||
| Comparator Group | 25 Infusions | |||
| Comparator Group | 3 Infusions | |||
| Switching Group | 8 Infusions | |||
| Switching Group | 6 Infusions | |||
| Switching Group | 0 Infusions | |||
| Switching Group | 86 Infusions | |||
| NCT02980042 | Multiple Sclerosis | Severity of IRRs Following the Day 15 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions Day 15, pre-study infusions | Comparator Group | 0 Infusions |
| Comparator Group | 172 Infusions | |||
| Comparator Group | 3 Infusions | |||
| Comparator Group | 25 Infusions | |||
| Switching Group | 4 Infusions | |||
| Switching Group | 96 Infusions | |||
| Switching Group | 0 Infusions | |||
| Switching Group | 0 Infusions | |||
| NCT02980042 | Multiple Sclerosis | Severity of IRRs Following the Week 24 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions Week 24, pre-study infusions | Comparator Group | 172 Infusions |
| Comparator Group | 3 Infusions | |||
| Comparator Group | 25 Infusions | |||
| Comparator Group | 0 Infusions | |||
| Switching Group | 3 Infusions | |||
| Switching Group | 9 Infusions | |||
| Switching Group | 88 Infusions | |||
| Switching Group | 0 Infusions | |||
| NCT02994927 ADVOCATE | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Percentage of Subjects Achieving Disease Remission at Week 26 Week 26 | Avacopan Group | 72.3 percentage of participants |
| Prednisone Group | 70.1 percentage of participants | |||
| NCT02994927 ADVOCATE | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Percentage of Subjects Achieving Sustained Disease Remission at Week 52 Week 52 | Avacopan Group | 65.7 percentage of participants |
| Prednisone Group | 54.9 percentage of participants | |||
| NCT03002038 | Neuromyelitis Optica | Annual Relapse Rate one year | Azathioprine | 1 Number of relapses (±0.38 Standard Deviation) |
| Azathioprine | 0.51 Number of relapses (±0.55 Standard Deviation) | |||
| Rituximab | 0.21 Number of relapses (±0.42 Standard Deviation) | |||
| Rituximab | 1.30 Number of relapses (±0.68 Standard Deviation) | |||
| NCT03078855 ILyAD | Leukemia, Lymphocytic, Chronic, B-Cell | Event Free Survival 3 years | Placebo Plus Rituximab | 49.5 Percentage of Participants |
| Vitamin D Plus Rituximab | 47.7 Percentage of Participants | |||
| NCT03112603 | Graft vs Host Disease | Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit Cycle 7 Day 1 (each cycle was comprised of 4 weeks) | Best Available Therapy | 25.6 percentage of participants |
| Ruxolitinib | 49.7 percentage of participants | |||
| NCT03312907 | Lupus Erythematosus, Systemic | Percentage of Participants With a State of Disease Control at Week 52 Week 52 | Belimumab + Placebo | 16.7 Percentage of participants |
| Belimumab + Rituximab | 19.4 Percentage of participants | |||
| Belimumab + Standard Therapy | 25.5 Percentage of participants | |||
| NCT03336333 SEQUOIA | Leukemia, Lymphocytic, Chronic, B-Cell | Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR) Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021) | Cohort 1: Bendamustine + Rituximab Without Del(17p) | 33.7 Months |
| Cohort 1: Zanubrutinib Without Del(17p) | NA Months | |||
| NCT03593902 CAST | Scleroderma, Systemic | Change in Skin Score by mRSS Pre Treatment and Post Treatment | Hematopoietic Stem Cell Transplantation | 25 units on a scale |
| Hematopoietic Stem Cell Transplantation | 16 units on a scale | |||
| NCT03976102 FLINTER | Lymphoma, Follicular | Best Overall Response Rate (BORR) for Low Tumor Burden Follicular Lymphoma Month 7 (Week 28) | Arm A: DRL_RI | 80.2 percentage of participants |
| Arm B: MabThera® | 79.4 percentage of participants | |||
| NCT04075292 | Leukemia, Lymphocytic, Chronic, B-Cell | Progression Free Survival (PFS) Assessed by BICR Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months) | Acalabrutinib | NA months |
| Chlorambucil Plus Rituximab | 15.54 months | |||
| NCT04182204 POLARGO | Lymphoma, Large B-Cell, Diffuse | Stage 1: Number of Participants With Adverse Events (AEs) From treatment initiation until 90 days after the last dose of study drug or initiation of non-protocol-specified anti-lymphoma treatment (NALT) (Up to approximately 8.3 months) | Stage 1: Pola-R-GemOx | 14 Participants |
| NCT04182204 POLARGO | Lymphoma, Large B-Cell, Diffuse | Stage 1: Number of Participants With Peripheral Neuropathy (PN) From treatment initiation until 90 days after the last dose of study drug or initiation of NALT (Up to approximately 8.3 months) | Stage 1: Pola-R-GemOx | 8 Participants |
| NCT04182204 POLARGO | Lymphoma, Large B-Cell, Diffuse | Stage 2: Overall Survival (OS) From randomization to death (Up to approximately 34 months) | Stage 2: Pola-R-GemOx | 19.5 months |
| Stage 2: R-GemOx | 12.5 months | |||
| NCT04236141 | Lymphoma, Large B-Cell, Diffuse | Percentage of Participants With Complete Response (CR) at the End of Treatment (EOT) Assessment Based on Positron Emission Tomography-Computed Tomography (PET-CT) Assessed by Independent Review Committee (IRC) Up to approximately 23 weeks | Placebo Plus Bendamustine and Rituximab | 14.3 percentage of participants |
| Polatuzumab Vedotin Plus Bendamustine and Rituximab | 25.0 percentage of participants | |||
| NCT04285567 CRISTALLO | Leukemia, Lymphocytic, Chronic, B-Cell | Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS) At Month 15 | Arm A: VEN+G | 81.3 percentage of participants |
| Arm B: FCR/BR | 54.7 percentage of participants | |||
| NCT04666038 BRUIN CLL-321 | Lymphoma | Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months) | Arm A - Pirtobrutinib | 13.96 Months |
| Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab | 8.74 Months | |||
| NCT04680052 InMIND | Lymphoma, Follicular | FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First up to 2 years | FL: Placebo + Rituximab + Lenalidomide | 54.0 percent probability |
| FL: Placebo + Rituximab + Lenalidomide | 78.2 percent probability | |||
| FL: Placebo + Rituximab + Lenalidomide | 31.8 percent probability | |||
| FL: Placebo + Rituximab + Lenalidomide | 38.5 percent probability | |||
| FL: Tafasitamab + Rituximab + Lenalidomide | 41.7 percent probability | |||
| FL: Tafasitamab + Rituximab + Lenalidomide | 79.0 percent probability | |||
| FL: Tafasitamab + Rituximab + Lenalidomide | 92.4 percent probability | |||
| FL: Tafasitamab + Rituximab + Lenalidomide | 61.9 percent probability | |||
| NCT04680052 InMIND | Lymphoma, Follicular | FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First up to approximately 34 months | FL: Placebo + Rituximab + Lenalidomide | 13.93 months |
| FL: Tafasitamab + Rituximab + Lenalidomide | 22.37 months | |||
| NCT05171647 SUNMO | Lymphoma, Non-Hodgkin | Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP) Up to approximately 23.8 months | Arm A: Mosun-Pola | 69.7 percentage of participants |
| Arm B: R-GemOx | 44.1 percentage of participants | |||
| NCT05171647 SUNMO | Lymphoma, Non-Hodgkin | Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans Up to 32 months | Arm A: Mosun-Pola | 11.5 months |
| Arm B: R-GemOx | 3.8 months |